Currently the only companion diagnostic available is an FDA approved test to determine tumor PDL-1 expression, but despite this selection 80% of patients show no clinical benefit (8), losing their opportunity to receive an effective treatment and suffering the elevated economic burden of this treatment. Here, CD274 is linked to neoplasm.